PlainRecalls
FDA Devices Moderate Class II Terminated

I-125 CE Marked QuickLink Cartridges; Sterile; Bard Brachysource Radioactive Seeds in QuickLink Cartridges Indicated for permanent interstitial treatment of selected localized tumors such as: head and neck, lung, pancreas, and early stage prostate. Implants are indicated to treat residual tumors following completion of a course of external radiation therapy and for recurrent tumors.

Reported: December 27, 2017 Initiated: December 9, 2016 #Z-0267-2018

Product Description

I-125 CE Marked QuickLink Cartridges; Sterile; Bard Brachysource Radioactive Seeds in QuickLink Cartridges Indicated for permanent interstitial treatment of selected localized tumors such as: head and neck, lung, pancreas, and early stage prostate. Implants are indicated to treat residual tumors following completion of a course of external radiation therapy and for recurrent tumors.

Reason for Recall

Activity and quantity of seeds sent in shipments were incorrect.

Details

Recalling Firm
C.R. Bard, Inc.
Units Affected
134 seeds
Distribution
Belgium & South Africa.
Location
Covington, GA

Frequently Asked Questions

What product was recalled?
I-125 CE Marked QuickLink Cartridges; Sterile; Bard Brachysource Radioactive Seeds in QuickLink Cartridges Indicated for permanent interstitial treatment of selected localized tumors such as: head and neck, lung, pancreas, and early stage prostate. Implants are indicated to treat residual tumors following completion of a course of external radiation therapy and for recurrent tumors.. Recalled by C.R. Bard, Inc.. Units affected: 134 seeds.
Why was this product recalled?
Activity and quantity of seeds sent in shipments were incorrect.
Which agency issued this recall?
This recall was issued by the FDA Devices on December 27, 2017. Severity: Moderate. Recall number: Z-0267-2018.